Novo Nordisk (NVO) has released an update.
Novo Nordisk reports a robust first quarter for 2024 with sales surging by 24% at constant exchange rates to DKK 65.3 billion, while operating profit soared by 30%. The growth is attributed to strong demand for its GLP-1 diabetes and obesity treatments. Additionally, the company has updated its full-year outlook, now expecting sales growth between 19-27% and an operating profit increase of 22-30% at constant exchange rates.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
